SEL1L and squamous cell carcinoma of the esophagus

Paola Granelli, Monica Cattaneo, Stefano Ferrero, Luca Bottiglieri, Silvano Bosari, Giuseppe Fichera, Ida Biunno

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The gene SEL1L is involved both in human breast and pancreatic cancer progression. It is located on 14q24.3-31, a region known to be lost in invasive cancer of the esophagus. We aimed to assess whether SEL1L could become a useful biomarker for this cancer. We assessed SEL1L mRNA and protein expression in 35 patients and found it to be weak in low-grade and strong in high-grade dysplasia. Although the majority of cancer patients showed differential expression (mRNA and protein) of SEL1L, in five cases it was completely absent; these patients had the worst outcomes. SEL1L immunoreactivity was negative in normal tissue samples from five patients with mild esophagitis as well as in normal mucosa adjacent to the tumor. We hypothesize that SEL1L could influence those cellular changes that mediate the transition from a normal mucosa to a neoplastic lesion and may help in the identification of those patients at higher risk of developing this cancer. The specific impact of SEL1L in esophageal cancer needs further investigation.

Original languageEnglish
Pages (from-to)5857-5861
Number of pages5
JournalClinical Cancer Research
Volume10
Issue number17
DOIs
Publication statusPublished - Sep 1 2004

Fingerprint

Esophagus
Squamous Cell Carcinoma
Esophageal Neoplasms
Mucous Membrane
Neoplasms
Messenger RNA
Esophagitis
Tumor Biomarkers
Pancreatic Neoplasms
Proteins
Breast Neoplasms
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

SEL1L and squamous cell carcinoma of the esophagus. / Granelli, Paola; Cattaneo, Monica; Ferrero, Stefano; Bottiglieri, Luca; Bosari, Silvano; Fichera, Giuseppe; Biunno, Ida.

In: Clinical Cancer Research, Vol. 10, No. 17, 01.09.2004, p. 5857-5861.

Research output: Contribution to journalArticle

@article{f3c78a12ec19457895146240f8e8bc15,
title = "SEL1L and squamous cell carcinoma of the esophagus",
abstract = "The gene SEL1L is involved both in human breast and pancreatic cancer progression. It is located on 14q24.3-31, a region known to be lost in invasive cancer of the esophagus. We aimed to assess whether SEL1L could become a useful biomarker for this cancer. We assessed SEL1L mRNA and protein expression in 35 patients and found it to be weak in low-grade and strong in high-grade dysplasia. Although the majority of cancer patients showed differential expression (mRNA and protein) of SEL1L, in five cases it was completely absent; these patients had the worst outcomes. SEL1L immunoreactivity was negative in normal tissue samples from five patients with mild esophagitis as well as in normal mucosa adjacent to the tumor. We hypothesize that SEL1L could influence those cellular changes that mediate the transition from a normal mucosa to a neoplastic lesion and may help in the identification of those patients at higher risk of developing this cancer. The specific impact of SEL1L in esophageal cancer needs further investigation.",
author = "Paola Granelli and Monica Cattaneo and Stefano Ferrero and Luca Bottiglieri and Silvano Bosari and Giuseppe Fichera and Ida Biunno",
year = "2004",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-04-0075",
language = "English",
volume = "10",
pages = "5857--5861",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - SEL1L and squamous cell carcinoma of the esophagus

AU - Granelli, Paola

AU - Cattaneo, Monica

AU - Ferrero, Stefano

AU - Bottiglieri, Luca

AU - Bosari, Silvano

AU - Fichera, Giuseppe

AU - Biunno, Ida

PY - 2004/9/1

Y1 - 2004/9/1

N2 - The gene SEL1L is involved both in human breast and pancreatic cancer progression. It is located on 14q24.3-31, a region known to be lost in invasive cancer of the esophagus. We aimed to assess whether SEL1L could become a useful biomarker for this cancer. We assessed SEL1L mRNA and protein expression in 35 patients and found it to be weak in low-grade and strong in high-grade dysplasia. Although the majority of cancer patients showed differential expression (mRNA and protein) of SEL1L, in five cases it was completely absent; these patients had the worst outcomes. SEL1L immunoreactivity was negative in normal tissue samples from five patients with mild esophagitis as well as in normal mucosa adjacent to the tumor. We hypothesize that SEL1L could influence those cellular changes that mediate the transition from a normal mucosa to a neoplastic lesion and may help in the identification of those patients at higher risk of developing this cancer. The specific impact of SEL1L in esophageal cancer needs further investigation.

AB - The gene SEL1L is involved both in human breast and pancreatic cancer progression. It is located on 14q24.3-31, a region known to be lost in invasive cancer of the esophagus. We aimed to assess whether SEL1L could become a useful biomarker for this cancer. We assessed SEL1L mRNA and protein expression in 35 patients and found it to be weak in low-grade and strong in high-grade dysplasia. Although the majority of cancer patients showed differential expression (mRNA and protein) of SEL1L, in five cases it was completely absent; these patients had the worst outcomes. SEL1L immunoreactivity was negative in normal tissue samples from five patients with mild esophagitis as well as in normal mucosa adjacent to the tumor. We hypothesize that SEL1L could influence those cellular changes that mediate the transition from a normal mucosa to a neoplastic lesion and may help in the identification of those patients at higher risk of developing this cancer. The specific impact of SEL1L in esophageal cancer needs further investigation.

UR - http://www.scopus.com/inward/record.url?scp=4444253793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444253793&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0075

DO - 10.1158/1078-0432.CCR-04-0075

M3 - Article

VL - 10

SP - 5857

EP - 5861

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -